Because Ned Said: FDA Is Sued Over Removal of Blockbuster Weight Loss Drug from Shortages List

In his latest article for Pharmacy Times, Ned Milenkovich, chair of Much’s Health Care group, examined a legal battle that ensued after the U.S. Food and Drug Administration (FDA) removed tirzepatide, a weight-loss drug, from its drug shortage list. He discusses the questions raised by the case, including how drug shortages are defined, the role of compounding pharmacies, and what happens when regulators, manufacturers, and pharmacies disagree about whether or not supply truly meets patient demand.